Digitisation | September 11, 2025
Lilly launches $1.1 billion TuneLab platform for AI-enabled drug discovery
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Subscribe To Our Newsletter & Stay Updated
